导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.58% | 1580/4773 |
| 近一周 | -2.24% | 1570/5462 |
| 近一月 | -3.84% | 2008/5421 |
| 近一季 | -6.23% | 2024/5209 |
| 近半年 | 1.15% | 1078/4920 |
| 近一年 | 6.59% | 1437/4366 |
| 近两年 | 52.62% | 1406/2954 |
| 近三年 | 31.50% | 993/2253 |
| 成立以来 | 55.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.66% 2853/4961 |
13.75% 1952/5312 |
- - |
- - |
| 2025 | 23.52% 1866/4813 |
-0.02% 2032/3635 |
1.94% 2002/4076 |
20.09% 2038/4524 |
0.92% 1657/4813 |
| 2024 | 12.67% 1222/3463 |
4.45% 454/2808 |
-1.85% 1117/3014 |
13.27% 2201/3129 |
-2.97% 2222/3463 |
| 2023 | -18.28% 1798/2656 |
4.73% 880/2280 |
-5.35% 1432/2385 |
-10.60% 2010/2515 |
-7.79% 2210/2655 |
| 2022 | -21.81% 1051/2207 |
-17.24% 1191/1919 |
10.94% 254/2016 |
-14.00% 1010/2113 |
-0.98% 1664/2208 |
| 2021 | -1.53% 806/1822 |
-1.17% 443/1255 |
7.59% 678/1330 |
-10.61% 1230/1466 |
3.61% 414/1822 |
| 2020 | 44.34% 228/1250 |
-5.47% 422/1028 |
21.06% 250/1067 |
12.39% 389/1164 |
12.23% 491/1184 |
| 2019 | 42.31% 217/1092 |
23.32% 560/739 |
-1.01% 285/788 |
5.37% 153/850 |
10.64% 110/918 |
| 2018 | -19.24% 157/834 |
- - |
-1.50% 49/631 |
-0.77% 197/660 |
-11.21% 264/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇安沪深300指数增强C VS. 长安沪深300非周期A(740101) |